(MENAFN- Investor Brand Network)
Biotechnology innovator BiondVax Pharmaceuticals recently provided a business update and published full-year financial results for the period ended December 31, 2022 Achievements realized to date leave CEO Amir Reichman optimistic about the company's growth potential and ability to deliver value to shareholders The company enjoys definitive, exclusive agreements including options for exclusive worldwide licenses with the Max Planck Society and the University Medical Center Göttingen, Germany to enable it to build a pipeline of 'biobetter' nanosized VHH antibodies (“NanoAbs”) Pipeline to target diseases with attractive commercial opportunities such as psoriasis, psoriatic arthritis, COVID-19, macular degeneration and asthma
biondvax pharmaceuticals (nasdaq: bvxv)
recently provided a business update, published its full-year financial results for the period ended December 31, 2022, and filed its annual report on Form 10-K with the Securities and Exchange Commission (“SEC”) ( ). The business update reflected recent highlights and achievements that company CEO Amir Reichman says leave him“optimistic about BiondVax's growth potential and ability to deliver value to our stakeholders.”
A developmental stage biotech company keen on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, BiondVax in late 2021 and early 2022 entered into definitive agreements with the...
NOTE TO INVESTORS:
The latest news and updates relating to BVXV are available in the company's newsroom at
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
bmw prime . As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text“Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit
San Francisco, California
BioMedWire is part of the
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.